Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Personalis stock
Own Personalis stock in just a few minutes.
Personalis, Inc is a diagnostics & research business based in the US. Personalis shares (PSNL) are listed on the NASDAQ and all prices are listed in US Dollars. Personalis employs 234 staff and has a trailing 12-month revenue of around USD$78.6 million.
How to buy shares in Personalis
- Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
- Search for Personalis. Find the stock by name or ticker symbol: PSNL. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Personalis reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Personalis, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Personalis. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
Personalis share price
Use our graph to track the performance of PSNL stocks over time.Personalis shares at a glance
Information last updated 2021-04-09.
| 52-week range | USD$7.8739 - USD$53.46 |
|---|---|
| 50-day moving average | USD$27.1832 |
| 200-day moving average | USD$31.3951 |
| Wall St. target price | USD$42 |
| PE ratio | 53.9512 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | USD$-4.736 |
Buy Personalis shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Personalis stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Is Personalis under- or over-valued?
Valuing Personalis stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Personalis's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Personalis's P/E ratio
Personalis's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 54x. In other words, Personalis shares trade at around 54x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Personalis financials
| Revenue TTM | USD$78.6 million |
|---|---|
| Gross profit TTM | USD$20.1 million |
| Return on assets TTM | -13.1% |
| Return on equity TTM | -27.37% |
| Profit margin | -52.49% |
| Book value | $3.577 |
| Market capitalisation | USD$1 billion |
TTM: trailing 12 months
Shorting Personalis shares
There are currently 3.1 million Personalis shares held short by investors – that's known as Personalis's "short interest". This figure is 34% up from 2.3 million last month.
There are a few different ways that this level of interest in shorting Personalis shares can be evaluated.
Personalis's "short interest ratio" (SIR)
Personalis's "short interest ratio" (SIR) is the quantity of Personalis shares currently shorted divided by the average quantity of Personalis shares traded daily (recently around 1.2 million). Personalis's SIR currently stands at 2.66. In other words for every 100,000 Personalis shares traded daily on the market, roughly 2660 shares are currently held short.
However Personalis's short interest can also be evaluated against the total number of Personalis shares, or, against the total number of tradable Personalis shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Personalis's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Personalis shares in existence, roughly 70 shares are currently held short) or 0.0974% of the tradable shares (for every 100,000 tradable Personalis shares, roughly 97 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Personalis.
Find out more about how you can short Personalis stock.
Personalis share dividends
We're not expecting Personalis to pay a dividend over the next 12 months.
Personalis overview
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics. The company also provides a complementary liquid biopsy assay that analyzes various human genes versus. It serves biopharmaceutical customers, universities and non-profits, diagnostics companies, and government entities. The company has partnership with Berry Genomics; Natera, Inc.; and MapKure, LLC. Personalis, Inc. was founded in 2011 and is headquartered in Menlo Park, California.
Frequently asked questions
More guides on Finder
-
How to buy Sigma Labs stock
Steps to owning and managing SGLB, with 24-hour and historical pricing before you buy.
-
How to buy Simpson Manufacturing CoInc stock
Steps to owning and managing SSD, with 24-hour and historical pricing before you buy.
-
How to buy Sequans Communications S-A stock
Steps to owning and managing SQNS, with 24-hour and historical pricing before you buy.
-
How to buy SFL Corporation stock
Steps to owning and managing SFL, with 24-hour and historical pricing before you buy.
-
How to buy Senmiao Technology stock
Steps to owning and managing AIHS, with 24-hour and historical pricing before you buy.
-
How to buy Sensata Technologies Holding stock
Steps to owning and managing ST, with 24-hour and historical pricing before you buy.
-
How to buy Select Bancorp stock
Steps to owning and managing SLCT, with 24-hour and historical pricing before you buy.
-
How to buy Second Sight Medical Products stock
Steps to owning and managing EYES, with 24-hour and historical pricing before you buy.
-
How to buy Sibanye Stillwater stock
Steps to owning and managing SBSW, with 24-hour and historical pricing before you buy.
-
How to buy Shinhan Financial Group CoLtd stock
Steps to owning and managing SHG, with 24-hour and historical pricing before you buy.
Ask an Expert